We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
American CryoStem Announces Breakthroughs in the Expansion and Lineage-Specific Differentiations of ADSCs
Product News

American CryoStem Announces Breakthroughs in the Expansion and Lineage-Specific Differentiations of ADSCs

American CryoStem Announces Breakthroughs in the Expansion and Lineage-Specific Differentiations of ADSCs
Product News

American CryoStem Announces Breakthroughs in the Expansion and Lineage-Specific Differentiations of ADSCs


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "American CryoStem Announces Breakthroughs in the Expansion and Lineage-Specific Differentiations of ADSCs"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Breakthroughs in American CryoStem’s proprietary cell culture medium (ACSelerate™) and culturing methodology have enabled the Company to accelerate the robust cellular expansion and rapid differentiation of ADSCs to adipocytes (fat cells), chondrocytes (cartilage-producing cells) and osteocytes (bone-producing cells). Working with its patented media technologies, the Company has been able to accelerate early adipocyte formation to within 24 to 72 hours; to produce chondrocyte filaments contracting into early cartilaginous tissue within 48 to 72 hours; and to form heavily mineralized, trabecular bone tissue within 11 days -- processes that typically require several weeks to complete.

Dr. Michael Moeller, Chief Scientist at American CryoStem, stated. “The development of rapid, efficient and reproducible methods of differentiating distinct mature cells from adipose tissue will prove invaluable to the Regenerative Medicine industry. The ability to quickly grow large numbers of ADSCs from patient samples and to rapidly differentiate them into distinct lineages will open the door to multiple therapeutic and regenerative approaches supported in our ongoing university and corporate collaborations.”

“We are pleased with our laboratory’s success in developing and improving the Company’s products for research and therapeutic applications. This improvement is significant to the industry in that rapid differentiation of harvested adipose derived stem cells can reduce the lead time for proper and complete identification of these cells from weeks to just days,” added Anthony Dudzinski, American CryoStem’s COO. Continuing, he noted, “Our goal is to improve and accelerate the movement of cellular therapies from the lab to the patient.”

Advertisement